Blood Pressure Wearables: The New Biohacking Boom

FDA relaxed oversight on wellness wearables. Now smart rings like Oura can estimate your blood pressure without medical approval. This changes the biohacking game.

The Science

Blood pressure is a key cardiovascular health marker. Traditionally, measuring it requires an inflatable cuff that wraps around the upper arm, a method that is uncomfortable and only provides spot readings. But new optical sensors, such as photoplethysmography (PPG), and AI algorithms can estimate blood pressure from blood flow in fingers or wrists. These sensors emit light that penetrates the skin and measures changes in blood volume, and algorithms correlate that data with systolic and diastolic pressure. The FDA now allows these estimates to be marketed as "wellness," as long as they don't make explicit medical claims, such as diagnosing hypertension.

Dr. Ricky Bloomfield, Oura's chief technology officer, confirmed the guidance gives them confidence to ship features sooner than planned. "Literally the same day we started internal conversations to accelerate development," he said in an interview. This accelerates technology that previously required months of regulatory review and costly clinical trials. The guidance, published in January 2026 during the Consumer Electronics Show (CES), represents a paradigm shift: the FDA is moving away from strict oversight for products that do not claim to treat or diagnose diseases, opening the door to a wave of innovation in the wellness sector.

“The FDA's new guidance allows wearables to estimate blood pressure without approval, opening the door to a wave of biohacking devices.”

Key Findings

• Key date: Guidance announced January 2026 at the Consumer Electronics Show in Las Vegas.
• Immediate impact: Oura began planning new features the same day, according to executive statements.
• Regulatory shift: FDA permits "estimate, infer, or output" blood pressure and glucose readings for wellness purposes, without prior authorization.
• Commissioner's statement: Marty Makary, FDA commissioner, said the agency will "get out of the way" of products not making medical claims, fostering innovation.
• Broader context: This guidance adds to a trend of deregulation in digital health, including continuous glucose monitors and heart rate devices.

Why It Matters

For biohackers, continuous blood pressure data without a cuff is a huge advance. It allows real-time monitoring of responses to stress, exercise, sleep, and supplements, something previously only possible in clinical settings. Imagine seeing how your blood pressure spikes after an argument or drops during meditation. This information can help optimize daily habits and detect early cardiovascular risk patterns. However, significant risks exist: estimates can be inaccurate, especially in people with conditions like arrhythmias or poor peripheral circulation. Users might make poor decisions if they trust blindly, such as adjusting medications without medical supervision.

The guidance reduces regulatory subjectivity but transfers responsibility to the user. It's crucial to understand these devices are not medical; they're optimization tools. Accuracy will vary by algorithm, hardware, and individual physiology. Preliminary studies show some devices have errors up to 10 mmHg compared to traditional cuffs, which could be clinically relevant. Therefore, biohackers must adopt a critical approach and supplement these readings with reference measurements.

Public Health Implications

Beyond individual biohacking, this deregulation could have public health implications. If wearables become accurate enough, they could enable mass screening for hypertension, a condition affecting millions undiagnosed. However, lack of oversight could also lead to an avalanche of unvalidated data that confuses users and healthcare professionals. The FDA has stated manufacturers cannot make medical claims, but in practice, the line between wellness and medicine is blurry. For example, a feature that alerts "high blood pressure" could be interpreted as a diagnosis, even though the device is not approved for that.

Your Protocol

To leverage this technology safely and effectively, follow these evidence-based steps:

1. 1Choose a validated device: Look for wearables with published accuracy studies in peer-reviewed journals, even if FDA approval isn't required. Oura, Apple Watch, and Samsung Galaxy Watch are benchmarks with public data. Verify the algorithm has been tested on diverse populations.
2. 2Cross-check with traditional measurements: Use a validated arm cuff (e.g., Omron) once a week to calibrate your estimates and detect drift. Log both readings in an app to identify error patterns.
3. 3Monitor trends, not absolutes: The greatest utility is seeing how your pressure changes with fasting, exercise, sleep, or supplement intake, not a single number. For instance, an upward trend over weeks might indicate chronic stress or need for dietary adjustment.
4. 4Contextualize with other data: Combine blood pressure readings with heart rate, heart rate variability (HRV), and sleep quality for a holistic picture. Oura already integrates these parameters.
5. 5Consult a professional: If you detect consistently high values (e.g., systolic >130 mmHg) or symptoms like dizziness, don't rely solely on the wearable. See a doctor for clinical evaluation.

What To Watch Next

The coming months will see a flood of firmware updates and new devices. Oura leads with its third-generation ring, but Samsung and Fitbit won't lag. Startups focused on glucose and blood pressure, like Levels and NutriSense, may integrate these metrics. The key question is whether accuracy will keep pace with speed. The FDA has promised to monitor the market and act if safety issues arise, but responsibility largely falls on manufacturers and users.

Additionally, the biohacking community is developing community validation protocols, where users share accuracy data on forums like Reddit and Discord. This could fill the regulatory gap but also introduces bias. Collaboration between academic researchers and wearable companies will be crucial to establish accuracy standards.

The Bottom Line

FDA deregulation accelerates innovation in health wearables. For the informed biohacker, it's an opportunity to get more data, but with the responsibility to interpret it critically. Monitor trends, not numbers, and combine with periodic clinical measurements. The future of self-tracking arrived faster than expected, and now it's up to us to use it wisely.